The Global Prostate Cancer Therapeutics Market size was valued at USD 18.12Billion in 2023 and the total Global Prostate Cancer Therapeutics Market revenue is expected to grow at a CAGR of 7.3% from 2024 to 2030, reaching nearly USD 29.73Billion.Global Prostate Cancer Therapeutics Market Overview
The prostate is an exocrine gland that is situated below the bladder and in front of the rectum in men and is an important part of the male reproductive system which gets larger as men age. Many conditions that affect the prostate are prostate cancer, prostatitis, and benign prostatic hyperplasia. Prostate cancer is the second most common type of cancer occurring in men. It is a serious health issue and it starts in the prostate gland and usually grows slowly. Luckily, many men are diagnosed before the cancer spreads, making treatment more effective. According to the U.S. Centers for Disease Control and Prevention (CDC), 13 out of every 100 men will get prostate cancer at some point in their lives. Each year, about 34,000 men in the United States die from prostate cancer.To know about the Research Methodology :- Request Free Sample Report The increase in patients among men for prostate cancer has increased the market due to early and timely detection of Prostate-specific antigen (PSA). The Prostate Cancer Therapeutics Market for many types of treatment including immunotherapy, chemotherapy, targeted therapy, and hormone therapy in the Global Prostate Cancer Therapeutics Market is growing. Due to advancements and developments in treatment options for prostate cancer patients, the mortality rate has drastically dropped with an increase in the recovery rate. All this is achievable due to early prostate cancer diagnosis and early detection leads to treatment and curing of cancer at early stages. This report on the Global Prostate Cancer Therapeutics Market provides detailed insights into its current state and future outlook. It includes a thorough analysis of key players, market dynamics, trends, challenges, and opportunities. The aim is to help stakeholders, pharmaceutical companies, healthcare providers, investors, policymakers, and researchers make informed decisions and create effective strategies to take advantage of market opportunities and address challenges in prostate cancer treatment.
Global Prostate Cancer Therapeutics Market Dynamics
Drivers Rising Occurrence of Prostate Cancer in Men Prostate Cancer in Males is the second most commonly occurring cancer among men. The number of people getting detected with prostate cancer and suffering from prostate cancer is rising, particularly in aging populations, with advancements in screening and diagnostic methods, are key drivers for the Global Prostate Cancer Therapeutics Market. As the number of patients is increasing the scope for treatment and therapeutic market is growing. Advancements in Treatment Options With technological advancements and improvement in R&D, the development of new and more effective drugs is transforming the picture of the Global Prostate Cancer Therapeutics Market. This has led to the development of new and more effective drugs with developments in hormone therapy, chemotherapy, immunotherapy, robot-assisted surgeries, and targeted therapies. These inventions improve the results of patients and drive demand in the market by offering more choices of treatments. Restraints Adverse Effects of Treatments Patients going through treatments for prostate cancer may face many side effects depending upon the type of treatment and severity of the cancer. These side effects may discourage patients from further taking treatments for the cancer. This also affects the effectiveness of the treatment creating a need for doctors to look out for alternate therapies to cure patients. Many patients undergoing hormone therapy for prostate cancer face problems of hot flashes, loss of bone density, and loss of muscle mass and physical strength. Some also lose interest in sex, or erectile dysfunction is seen. This is a major problem that companies can face and need to look upon to improvise in the Global Prostate Cancer Therapeutics Market. High Cost of Treatment Many treatments and therapies related to prostate cancer require high cost especially treatments done through the method of novel targeted therapies and immune therapies which is expensive for some patients to afford treatments. This also limits market access in regions where patients cannot afford such expensive treatments or regions where resources are limited. This is a huge drawback in the healthcare system where more research and development need to be done to find more affordable and cheaper alternatives to the existing treatment options available in the Global Prostate Cancer Therapeutics Market. Opportunities Increasing Demand for Personalized Medicine The severity of cancer and coping mechanisms of treatments given to patients vary from patient to patient depending upon their genetic makeup, previous medical history, and the combination of medicines consumed for other symptoms and diseases they have. So, the trend of personalized medicines is quickly increasing where personalized treatment is recommended to patients based on their genetic makeup, previous medical history, and any other disease or medical condition they possess along with prostate cancer taking their coping mechanism into account. Personalised therapies lead to more effective and targeted therapies which show speedy recovery in patients. This also increases the demand for specialized drugs and demand for specialized drugs increases too in the Global Prostate Cancer Therapeutics Market. Personalized treatments show speedy recovery in patients with comparatively fewer side effects. Advancements in Biomarker Research Technological advancements in the Global Prostate Cancer Therapeutics Market are driving market growth. Recent advancements like ongoing research into Prostate cancer biomarkers and treatment strategies towards precession medicines have potential for treatment. Individual genomic profiling is done and target-specific cancer pathways are studied for which genome editing tools, non-coding RNA biomarkers, and liquid tumor profiling are used. Research is done for the use of biomarkers for prostate cancer diagnosis, prognosis, and treatment response prediction. The introduction of prostate-specific antigen (PSA) has enabled early detection and decreased mortality among patients suffering from prostate cancer. Challenges Clinical Trial Failures Failure of clinical trials poses a big challenge in the healthcare industry for the treatment of prostate cancer in the Global Prostate Cancer Therapeutics Market. Where one in every five cancer clinical trials fails due to various reasons. Many cancer trials enter phases 2 & 3 but do not end up entering the market. Many times, trials fail because fewer patients enroll themselves for trial and do not want to take risks. As the number of patients enrolled is scientists do not have enough patients to study and collect data for. Improving enrolment in cancer clinical trials has promise to benefit patients and science to progress. A high failure rate of clinical trials leads to delays and problems in drug development and market entry. Based on End User & Distribution Channel: Based on end user type, the segment is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies have the biggest part of the global prostate cancer treatment market. The main reason for this is the increasing number of patients are on the lookout for medical care in hospitals. Based on the distribution channel, the Global Prostate Cancer Therapeutics Market is split into hospital pharmacies, retail pharmacies, and online pharmacies. Right now, hospital pharmacies dominate the prostate cancer treatment market due to their widespread presence worldwide, growing numbers of prostate cancer patients in hospitals, and the convenience they offer. Online pharmacies are the fastest growing segment as more people become aware of them, more people use the internet, and more people prefer buying drugs online rather than in person. With the largest revenue share in the global prostate cancer therapeutics market, hospital pharmacies are the major industry players. By managing drugs and ensuring quick access to supplies and medications, they perform an essential role in hospitals. Treatment for a variety of diseases is made convenient by these pharmacies, which provide services to both inpatient and outpatient patients. Along with lowering total prescription costs, their goal is to increase revenue from pharmaceutical sales and decrease errors in clinical decision-making.Global Prostate Cancer Therapeutics Market Regional Insights
In this report market scenarios of regions are compared, studied, and illustrated of regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Region-specific market dynamics are explained where how regulatory frameworks and reimbursement policies play a role and drive demand in the Global Prostate Cancer Therapeutics Market. North America currently dominates the global Prostate Cancer Therapeutics market because it has the largest population of patients suffering from prostate cancer. The launch of potential new medications in the fields of hormone therapy and biologics further drives the growth. A significant development, for example, is the US FDA's approval of Pluvicto's advanced accelerator application for the treatment of adult prostate cancer patients. With the projected launch of multiple pipeline medications during the projection period, the area is anticipated to maintain its market-leading position. Furthermore, North America's position as a leader in market growth is made stronger by strong government funding for innovation and the presence of significant firms providing prostate cancer therapies. Meanwhile, Asia-Pacific (APAC) and South America are projected to experience gradual growth in this market as awareness of the disease improves. Europe is expected to see significant expansion due to its higher incidence of prostate cancer and advanced healthcare infrastructure. In Europe, prostate cancer is the most frequently diagnosed cancer in men and ranks third among causes of cancer-related deaths in men. The incidence of prostate cancer diagnosis varies significantly across different regions, primarily influenced by the frequency of prostate-specific antigen (PSA) testing and international guidelines on screening. It is highest in Australia/New Zealand, Northern America, Western Europe, and Northern Europe. In contrast, incidence rates are low in Eastern and South-Central Asia, although they are rising. Eastern and Southern Europe have historically had lower rates, but these have been steadily increasing. Apart from PSA testing, factors such as age demographics, geographical location, and ethnicity also play crucial roles in determining incidence rates. Prostate cancer mortality rates are less diverse worldwide, typically higher in African-descent groups (the Caribbean and Sub-Saharan Africa, for example), intermediate in the USA, and significantly lower in Asia, especially South-Central Asia. While mortality due to prostate cancer has decreased in many Western countries, the extent of this reduction varies across different nations.Prostate Cancer Therapeutics Market Scope: Inquire before buying
Global Prostate Cancer Therapeutics Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 18.12 Bn. Forecast Period 2024 to 2030 CAGR: 7.3% Market Size in 2030: US $ 29.73 Bn. Segments Covered: by Drug Class Chemotherapy Targeted Therapy Immunotherapy Hormone Therapy by Distribution Channel Hospital Pharmacy Drug Store & Retail Pharmacy Online Pharmacy by End User Clinics Hospitals Others Prostate Cancer Therapeutics Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)Global Prostate Cancer Therapeutics Key Players
1. Ipsen Pharma 2. Astellas Pharma Inc. 3. Takeda Pharmaceutical Company Ltd. 4. Bayer AG 5. Bristol-Myers Squibb Company 6. Ferring Pharmaceuticals Inc. 7. AstraZeneca plc 8. Johnson & Johnson 9. F. Hoffmann-La Roche AG 10. GlaxoSmithKline Plc 11. EUSA Pharma,Inc. 12. Paladin Labs Inc. 13. Amgen Inc. 14. Cell Genesys Inc. 15. Spectrum Retail Pharmacy, Inc. 16. Indevus Retail Pharmacy Inc. 17. Dendreon Corporation 18. Genentech Inc. 19. Abbott Laboratories 20. Pfizer Inc. 21. Immunomedics, Inc. 22. Sanofi-Aventis SA 23. Novartis AG Frequently Asked Questions: 1] What segments are covered in the Global Prostate Cancer Therapeutics Market report? Ans. The segments covered in the Global Prostate Cancer Therapeutics Market report are based on Drug class, Distribution Channel, and Region. 2] Which region held the largest Global Prostate Cancer Therapeutics Market share in 2023? Ans. The North America region held the largest Global Prostate Cancer Therapeutics Market share in 2023. 3] What is the expected Global Prostate Cancer Therapeutics Market size by 2030? Ans. The Global Prostate Cancer Therapeutics Market size is expected to reach US$ 29.73 billion by 2030. 4] What was the key driver of the Global Prostate Cancer Therapeutics Market? Ans. The Rising Prevalence of Prostate Cancer and Advancements in Treatment Options are a major driver. 5] What is the expected CAGR of the Global Prostate Cancer Therapeutics Market during the forecast period? Ans. The expected CAGR of the Global Prostate Cancer Therapeutics Market is 7.3% during the forecast period.
1. Prostate Cancer Therapeutics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Prostate Cancer Therapeutics Market: Dynamics 2.1. Prostate Cancer Therapeutics Market Trends by Region 2.1.1. North America Prostate Cancer Therapeutics Market Trends 2.1.2. Europe Prostate Cancer Therapeutics Market Trends 2.1.3. Asia Pacific Prostate Cancer Therapeutics Market Trends 2.1.4. Middle East and Africa Prostate Cancer Therapeutics Market Trends 2.1.5. South America Prostate Cancer Therapeutics Market Trends 2.2. Prostate Cancer Therapeutics Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Prostate Cancer Therapeutics Market Drivers 2.2.1.2. North America Prostate Cancer Therapeutics Market Restraints 2.2.1.3. North America Prostate Cancer Therapeutics Market Opportunities 2.2.1.4. North America Prostate Cancer Therapeutics Market Challenges 2.2.2. Europe 2.2.2.1. Europe Prostate Cancer Therapeutics Market Drivers 2.2.2.2. Europe Prostate Cancer Therapeutics Market Restraints 2.2.2.3. Europe Prostate Cancer Therapeutics Market Opportunities 2.2.2.4. Europe Prostate Cancer Therapeutics Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Prostate Cancer Therapeutics Market Drivers 2.2.3.2. Asia Pacific Prostate Cancer Therapeutics Market Restraints 2.2.3.3. Asia Pacific Prostate Cancer Therapeutics Market Opportunities 2.2.3.4. Asia Pacific Prostate Cancer Therapeutics Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Prostate Cancer Therapeutics Market Drivers 2.2.4.2. Middle East and Africa Prostate Cancer Therapeutics Market Restraints 2.2.4.3. Middle East and Africa Prostate Cancer Therapeutics Market Opportunities 2.2.4.4. Middle East and Africa Prostate Cancer Therapeutics Market Challenges 2.2.5. South America 2.2.5.1. South America Prostate Cancer Therapeutics Market Drivers 2.2.5.2. South America Prostate Cancer Therapeutics Market Restraints 2.2.5.3. South America Prostate Cancer Therapeutics Market Opportunities 2.2.5.4. South America Prostate Cancer Therapeutics Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Prostate Cancer Therapeutics Industry 2.8. Analysis of Government Schemes and Initiatives For Prostate Cancer Therapeutics Industry 2.9. Prostate Cancer Therapeutics Market Trade Analysis 2.10. The Global Pandemic Impact on Prostate Cancer Therapeutics Market 3. Prostate Cancer Therapeutics Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 3.1.1. Chemotherapy 3.1.2. Targeted Therapy 3.1.3. Immunotherapy 3.1.4. Hormone Therapy 3.2. Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 3.2.1. Hospital Pharmacy 3.2.2. Drug Store & Retail Pharmacy 3.2.3. Online Pharmacy 3.3. Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 3.3.1. Clinics 3.3.2. Hospitals 3.3.3. Others 3.4. Prostate Cancer Therapeutics Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Prostate Cancer Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 4.1.1. Chemotherapy 4.1.2. Targeted Therapy 4.1.3. Immunotherapy 4.1.4. Hormone Therapy 4.2. North America Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.2.1. Hospital Pharmacy 4.2.2. Drug Store & Retail Pharmacy 4.2.3. Online Pharmacy 4.3. North America Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 4.3.1. Clinics 4.3.2. Hospitals 4.3.3. Others 4.4. North America Prostate Cancer Therapeutics Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 4.4.1.1.1. Chemotherapy 4.4.1.1.2. Targeted Therapy 4.4.1.1.3. Immunotherapy 4.4.1.1.4. Hormone Therapy 4.4.1.2. United States Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.1.2.1. Hospital Pharmacy 4.4.1.2.2. Drug Store & Retail Pharmacy 4.4.1.2.3. Online Pharmacy 4.4.1.3. United States Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 4.4.1.3.1. Clinics 4.4.1.3.2. Hospitals 4.4.1.3.3. Others 4.4.2. Canada 4.4.2.1. Canada Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 4.4.2.1.1. Chemotherapy 4.4.2.1.2. Targeted Therapy 4.4.2.1.3. Immunotherapy 4.4.2.1.4. Hormone Therapy 4.4.2.2. Canada Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.2.2.1. Hospital Pharmacy 4.4.2.2.2. Drug Store & Retail Pharmacy 4.4.2.2.3. Online Pharmacy 4.4.2.3. Canada Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 4.4.2.3.1. Clinics 4.4.2.3.2. Hospitals 4.4.2.3.3. Others 4.4.3. Mexico 4.4.3.1. Mexico Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 4.4.3.1.1. Chemotherapy 4.4.3.1.2. Targeted Therapy 4.4.3.1.3. Immunotherapy 4.4.3.1.4. Hormone Therapy 4.4.3.2. Mexico Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.3.2.1. Hospital Pharmacy 4.4.3.2.2. Drug Store & Retail Pharmacy 4.4.3.2.3. Online Pharmacy 4.4.3.3. Mexico Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 4.4.3.3.1. Clinics 4.4.3.3.2. Hospitals 4.4.3.3.3. Others 5. Europe Prostate Cancer Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.2. Europe Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.3. Europe Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4. Europe Prostate Cancer Therapeutics Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.1.2. United Kingdom Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.1.3. United Kingdom Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.2. France 5.4.2.1. France Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.2.2. France Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.2.3. France Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.3.2. Germany Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.3.3. Germany Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.4.2. Italy Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.4.3. Italy Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.5.2. Spain Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.5.3. Spain Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.6.2. Sweden Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.6.3. Sweden Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.7.2. Austria Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.7.3. Austria Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 5.4.8.2. Rest of Europe Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.8.3. Rest of Europe Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6. Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.2. Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.3. Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4. Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.1.2. China Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.1.3. China Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.2.2. S Korea Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.2.3. S Korea Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.3.2. Japan Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.3.3. Japan Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.4. India 6.4.4.1. India Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.4.2. India Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.4.3. India Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.5.2. Australia Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.5.3. Australia Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.6.2. Indonesia Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.6.3. Indonesia Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.7.2. Malaysia Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.7.3. Malaysia Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.8.2. Vietnam Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.8.3. Vietnam Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.9.2. Taiwan Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.9.3. Taiwan Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 6.4.10.2. Rest of Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.10.3. Rest of Asia Pacific Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 7. Middle East and Africa Prostate Cancer Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 7.2. Middle East and Africa Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.3. Middle East and Africa Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 7.4. Middle East and Africa Prostate Cancer Therapeutics Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 7.4.1.2. South Africa Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.1.3. South Africa Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 7.4.2.2. GCC Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.2.3. GCC Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 7.4.3.2. Nigeria Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.3.3. Nigeria Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 7.4.4.2. Rest of ME&A Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.4.3. Rest of ME&A Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 8. South America Prostate Cancer Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 8.2. South America Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.3. South America Prostate Cancer Therapeutics Market Size and Forecast, by End User(2023-2030) 8.4. South America Prostate Cancer Therapeutics Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 8.4.1.2. Brazil Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.1.3. Brazil Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 8.4.2.2. Argentina Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.2.3. Argentina Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Prostate Cancer Therapeutics Market Size and Forecast, by Drug Class (2023-2030) 8.4.3.2. Rest Of South America Prostate Cancer Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.3.3. Rest Of South America Prostate Cancer Therapeutics Market Size and Forecast, by End User (2023-2030) 9. Global Prostate Cancer Therapeutics Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Prostate Cancer Therapeutics Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Ipsen Pharma 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Astellas Pharma Inc. 10.3. Takeda Pharmaceutical Company Ltd. 10.4. Bayer AG 10.5. Bristol-Myers Squibb Company 10.6. Ferring Pharmaceuticals Inc. 10.7. AstraZeneca plc 10.8. Johnson & Johnson 10.9. F. Hoffmann-La Roche AG 10.10. GlaxoSmithKline Plc 10.11. EUSA Pharma,Inc. 10.12. Paladin Labs Inc. 10.13. Amgen Inc. 10.14. Cell Genesys Inc. 10.15. Spectrum Retail Pharmacy, Inc. 10.16. Indevus Retail Pharmacy Inc. 10.17. Dendreon Corporation 10.18. Genentech Inc. 10.19. Abbott Laboratories 10.20. Pfizer Inc. 10.21. Immunomedics, Inc. 10.22. Sanofi-Aventis SA 10.23. Novartis AG 11. Key Findings 12. Industry Recommendations 13. Prostate Cancer Therapeutics Market: Research Methodology 14. Terms and Glossary